Landiolol for Treating Arrhythmias: A State-of-The-Art Review
Muhammad Ghallab1, Mahmoud Samy Ahmed2, Talia H Ostrow3
1From the Department of Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY.
Cardiology in Review
|March 13, 2024
Summary
Landiolol, a cardioselective beta-blocker, shows promise for treating various arrhythmias due to its short half-life and minimal blood pressure effects. Further research is needed to optimize its use and explore its broader therapeutic potential.
Area of Science:
- Pharmacology and Therapeutics
- Cardiology
- Critical Care Medicine
Background:
- Landiolol is a novel ultra-short-acting beta-blocker.
- It exhibits high cardioselectivity and a short half-life.
- Its unique properties differentiate it from traditional beta-blockers.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, and pharmacodynamics of landiolol.
- To compare landiolol with conventional beta-blockers, such as esmolol.
- To explore landiolol's current and potential clinical applications in arrhythmia management and beyond.
Main Methods:
- Literature review of landiolol's properties and clinical studies.
- Analysis of pharmacology, pharmacokinetics, and pharmacodynamics.
- Examination of efficacy in preventing postoperative atrial fibrillation and managing tachyarrhythmias.
Main Results:
- Landiolol demonstrates high cardioselectivity, a short half-life, and minimal impact on blood pressure.
- Clinical trials show efficacy in preventing postoperative atrial fibrillation.
- Potential applications include rate control for atrial fibrillation/flutter and managing sepsis-related tachyarrhythmias.
Conclusions:
- Landiolol offers a promising alternative for arrhythmia treatment, especially in specific clinical scenarios.
- Its potential extends to anti-inflammatory, antioxidative, analgesic, and anticancer effects.
- Further research is required to optimize dosing, identify patient populations, and understand its mechanisms.
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
992
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
992
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
743
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
743
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
446
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
446
01:26Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584